Clinical Trial Corner

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

A clinical trial just kicked off, analyzing Padcev in patients with advanced, unresectable bladder cancer.

Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.

After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.

The first patient was dosed with lerapolturev in a phase 1/2 clinical trial evaluating the drug in patients with bladder cancer and other solid tumors.

A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.

The treatment previously demonstrated significantly improved overall survival for patients with recurrent glioblastoma in a phase 1 study.

VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.

Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.

The multicenter study is evaluating the safety and efficacy of nanrilkefusp alfa combined with Erbitux.

An oncolytic virus engineered to kill cancer cells was administered to a patient with pancreatic ductal adenocarcinoma as part of a phase 2b trial.

The trial is evaluating the safety and efficacy of AVB-001 patients with relapsed refractory ovarian cancer.

The COVALENT-102 trial will investigate BMF-219 in patients with non-small cell lung cancer, colorectal and pancreatic cancers.

Investigators have administered Keytruda and ONC-392 the first patients with platinum resistant ovarian cancer.

A phase 2 trial evaluating EVX-01 plus Keytruda (pembrolizumab) in patients with metastatic melanoma may continue, the FDA said.

Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers.

The combination met its main goal of progression-free survival and secondary goal of overall survival.

A recently launched clinical trial of NTX1088 will determine if the novel drug can help overcome immune checkpoint inhibition resistance in patients with locally advanced or metastatic solid tumors.

The first patient was enrolled in a phase 1 trial analyzing MTX110 in patients with recurrent glioblastoma, an aggressive type of brain cancer.

A phase 2 clinical trial will evaluate iadademstat for patients with relapsed or refractory high-grade neuroendocrine carcinoma.

A novel drug, MRT-2359, will be studied in a phase 1/2 trial for patients with MYC-driven cancers.

Patients with breast cancer can enroll on a clinical trial analyzing elinzanetant for endocrine therapy-related hot flashes.

A clinical trial will determine if chemotherapy plus 5-fraction MRIdian SMART will improve survival over chemotherapy alone in patients with locally advanced pancreatic cancer.

The study investigators will review the efficacy of [Lu-177]-PNT2002, a radioligand treatment, compared with Zytiga or Xtandi in patients with metastatic castration-resistant prostate cancer.

A clinical trial recently kicked off to study the effects of combining the novel drug BBP-398 plus Lumakras in patients with lung cancer that harbors a KRAS G12 mutation.

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

NC410 plus Keytruda will be studied in a phase 1b/2 trial for patients with certain solid cancers that either did not respond to or have not been treated with an immunotherapy agent.

The FDA granted a fast track designation to an investigational drug alone and in combination with Keytruda to treat patients with HPV recurrent/metastatic head and neck squamous cell carcinoma.